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Amyotrophic lateral sclerosis (ALS) is the most common degenerative motor neuron disorder. Although most cases of ALS are sporadic, 5–10% of cases are familial, with mutations
associated with over 40 genes. There is variation of ALS symptoms within families carrying
the same mutation; the disease may develop in one sibling and not in another despite the
presence of the mutation in both. Although the cause of this phenotypic variation is
unknown, it is likely related to genetic modifiers of disease expression. The identification of
ALS causing genes has led to the development of transgenic mouse models of motor neuron disease. Similar to families with familial ALS, there are background-dependent differences in disease phenotype in transgenic mouse models of ALS suggesting that, as in
human ALS, differences in phenotype may be ascribed to genetic modifiers. These genetic
modifiers may not cause ALS rather their expression either exacerbates or ameliorates the
effect of the mutant ALS causing genes. We have reported that in both the G93A-hSOD1
and G59S-hDCTN1 mouse models, SJL mice demonstrated a more severe phenotype than
C57BL6 mice. From reciprocal intercrosses between G93A-hSOD1 transgenic mice on SJL
and C57BL6 strains, we identified a major quantitative trait locus (QTL) on mouse chromosome 17 that results in a significant shift in lifespan. In this study we generated reciprocal
intercrosses between transgenic G59S-hDCTN1 mice on SJL and C57BL6 strains and identified survival QTLs on mouse chromosomes 17 and 18. The chromosome 17 survival QTL
on G93A-hSOD1 and G59S-hDCTN1 mice partly overlap, suggesting that the genetic modifiers located in this region may be shared by these two ALS models despite the fact that
motor neuron degeneration is caused by mutations in different proteins. The overlapping
region contains eighty-seven genes with non-synonymous variations predicted to be deleterious and/or damaging. Two genes in this segment, NOTCH3 and Safb/SAFB1, have been
associated with motor neuron disease. The identification of genetic modifiers of motor
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neuron disease, especially those modifiers that are shared by SOD1 and dynactin-1 transgenic mice, may result in the identification of novel targets for therapies that can alter the
course of this devastating illness.

Introduction
Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disease (MND) resulting
in progressive paralysis, muscle atrophy, and ultimately death, with a median survival of less
than five years. However, there is variability in ALS severity, with 20% of patients living longer
than five years and 10% of patients living 10 years or more. Although most cases of ALS are
sporadic (SALS), approximately 5–10% of ALS cases are familial (FALS), with mutations associated with over 40 genes [1–4]. There is also wide variation of ALS symptoms even within
families carrying the same familial mutation; the disease may develop in one sibling and not in
another despite the presence of the same mutation in both. Although the cause of this phenotypic variation has not been determined, it is likely related to genetic modifiers of disease
expression inherent in the genetic heterogeneity even within members of the same family.
Mutations in the Cu/Zn superoxide dismutase (SOD1) gene were the first identified in
FALS [5, 6]. The identification of SOD1 mutations led to the development of a transgenic
mouse model of ALS carrying the human G93A mutant allele [7]. These mice develop motor
neuron pathology and clinical symptoms remarkably similar to those seen in ALS patients [8–
11]. Similar to families with SOD1 mutations, there are background-dependent differences in
disease phenotype in transgenic G93A-hSOD1 mice. We have previously reported that the
G93A-hSOD1 transgene in ALR/LtJ, NOD.Rag1KO, SJL/J or C3H/HeJ backgrounds show a
more severe phenotype whereas a milder phenotype is observed in C57BL6 (B6), C57BL/
10ScSnJ (B10), BALB/cByJ and DBA/2J inbred strains [12, 13]. Utilizing these mouse strains,
we identified a major quantitative trait locus (QTL) on mouse chromosome (Chr) 17 that
results in a significant shift in lifespan [14], suggesting that, as in human ALS, the differences
in phenotype can be ascribed to genetic modifiers of motor neuron disease.
The identification of other FALS associated mutations has led to additional animal models
of motor neuron disease such as the mutant (G59S) human dynactin p150Glued transgenic
mouse (G59S-hDCTN1). This model is based on a slowly progressive, autosomal dominant
lower motor neuron variant of FALS in humans that is linked to a mutation in the p150Glued
subunit of the dynactin complex [15]. Transgenic mice that carry the mutated human dynactin-1 transgene (G59S-hDCTN1) demonstrate pathologic changes and clinical features seen in
SALS [16, 17]. These mice develop spontaneous tremors between five and six months of age.
Once near end-stage of the disease, the mice start to lose weight, stop grooming, and eventually
become paralyzed [16]. Similar to our finding in G93A-hSOD1 mice [12, 13], we observed a
more severe phenotype with significant acceleration of disease onset and age of death in G59ShDCTN1 mice bred onto the SJL background and a milder phenotype with delayed onset and
extended lifespan when bred onto the B6 background [18].
In this study, we report the results of QTL analysis of an intercross between G59S-hDCTN1
transgenic mice on a resistant (C57BL/6J) and a susceptible (SJL/J) mouse strain.

Materials and methods
Animals
Mice from two inbred strains were used in this study: C57BL/6J (B6) and SJL/J (SJL). G59ShDCTN1 mice were originally produced by Dr. Philip C. Wong at The Johns Hopkins
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University School of Medicine by injecting the transgene containing the G59S substitution
into fertilized eggs from C57BL6/SJL F1 hybrid mice [17]. The mice were then maintained on
a mixed B6xSJL/F1 background. From these mice, we developed two inbred strains (C57BL/6J
and SJL/J) by backcrossing the original mixed B6/SJL mice to either pure B6 or SJL for seven
generations [18]. An intercross was generated from short-(SJL), and long-(B6) lived strains for
mapping of quantitative trait loci that modify the onset and survival of G59S-hDCTN1 transgenic mice. The F1 mice were derived from crosses in both directions [SJL ♀ x B6 ♂] and [B6 ♀
x SJL ♂] and in all but one litter, the transgene was carried in the male. From the F1 cross, 167
F2 mice were generated. The F2 generation is the first generation where both parental phenotypes occur for an autosomal gene. In an autosomal gene there are four possible genotypes
B6xB6 (BB), B6xSJL or SJLxB6 (BS) and SJLxSJL (SS). Thus, in an F2 cross at any location of
an autosomal gene, the genotype is such that at that location 25% of the mice are BB, 50% BS
and 25% SS. This is not the case for the sex chromosomes. One of the X chromosomes in all
females but not males carry the paternal grandmother (pgm) X chromosome (either all S or all
B). At the other X chromosome, any region can be either B or S depending on cross over
events. In males, the Y chromosome is always that of the paternal grandfather (either all S or
all B).
The mice were maintained in humidity- and temperature-controlled rooms and fed PicoLab rodent diet 20 ad libitum with free access to water. The mice were genotyped using DNA
isolated from a 0.5 cm piece of mouse tail. Isolation was performed with the Qiagen DNeasy
Blood & Tissue Kit (Qiagen, Germantown, MD 20874). All animal studies were approved by
the Institutional Animal Care and Use Committee (IACUC) of Temple University and were
carried out in accordance with the National Institute of Health guide for the care and use of
laboratory animals.

Genotyping
The presence of the G59S-hDCTN1 transgene was determined by PCR as previously described
[17]. When breeding mice each carrying one copy of the G59S-hDCTN1 transgene, the transgene copy number of the offspring was determined by quantitative real-time PCR using mouse
IL-2 as a reference gene as previously described [19]. Assays were performed, in duplicate, on
a Chromo 4 Quantitative PCR System (Bio-Rad, Hercules, CA). For the QTL analysis, the F2
mice were genotyped with 136 SNPs across the genome that differentiate C57BL/6J from SJL/J
mice (S1 Table).

Life span
Life span was defined as age of sacrifice for any reason. Mice were sacrificed when they demonstrated limb paralysis or were unable to right themselves in 10 seconds when placed on their
side. In addition, mice were also euthanized if their health deteriorated to a degree such that
the veterinary staff recommended euthanasia. We differentiated between these two phenotypes. Euthanasia due to limb paralysis or inability to right themselves was defined as “survival”, whereas euthanasia due to health deterioration was defined as “health sacrifice”
(health_sac). Euthanasia was performed by an overdose of CO2 followed by cervical dislocation. All efforts were taken to minimize pain and discomfort. Progressive deterioration of the
animals’ health leading to death was not allowed. Natural death was not an end point in this
study.
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QTL analysis
QTL analysis was performed using R/QTL version 1.46.2 [20] running in R for Windows version 4.0.5. A book by Broman and Sen provides a review of statistical QTL mapping in experimental crosses and is an excellent guide to the use of the R/qtl software package [21]. For onedimensional scans, pseudo-markers were generated at 2 centimorgan (cM) spacing for each
Chr using the Carter–Falconer map function and whole genome scans were performed using
128 imputations [22]. One thousand permutations were performed to determine the thresholds for QTL detection [23]. Logarithm of the odds (LOD) scores were calculated with no
covariates and with the inclusion of sex and the paternal grandmother (pgm) of the F2 cross as
both additive and interactive covariates. Four thresholds 1%, 5%, 10% and 63% were calculated
from the permutation results. QTL with LOD score above the 1% threshold were considered
significant, while those above the 63% threshold were considered suggestive [24].
For two-dimensional scans, pair wise scans were performed using 2 cM spacing. All possible pairs of QTL locations on each Chr were tested for association with the life span. The likelihood from the full model (pseudo-marker pair and the interaction between them) and the null
model (no genetic effect) was compared and LOD scores were calculated.
QTL and possible QTL� QTL interactions identified from single QTL scan and pair wise
scan were fit into multiple regression models. By doing so, variations of the phenotype in the
models were estimated. P values for terms in the multiple regression model were calculated.
Terms were dropped sequentially until all the terms in the model were significant at 1% level
(p<0.01) for main QTL effects and 0.1% (p<0.001) for the interaction effects. The position of
the QTL was refined using the refine QTL command. This routine iteratively scans the QTL to
identify the positions with the maximum LOD score.

Genomic variations
The SJL sequence was obtained in BAM format from the Sanger Institute web site (https://
www.sanger.ac.uk/data/mouse-genomes-project/). Sequence variation (SNPs, insertions and
deletions) were determined in the QTL regions with samtools and bcftools [25] using the
genome sequence file for SJL and the C57BL6 reference genome as inputs. Variations in the
coding regions were determined using PROVEAN [26] (http://provean.jcvi.org/index.php).
PROVEAN was also used to determine variations that resulted in non-synonymous protein
changes as well as changes predicted to be deleterious and/or damaging.

Statistics
Significance between groups was determined by analysis of variance (ANOVA) using the
Tukey-Kramer post-hoc multiple comparison test. The data was considered significantly different if p< 0.05 unless otherwise noted. Statistical calculations were accomplished with the
aid of SYSTAT version 13 (SYSTAT Software Inc., Chicago, IL).

Results
Effect of genetic background on lifespan
We have previously shown that G59S-hDCTN1 mice demonstrate a shortened lifespan when
bred on a SJL background (273.3 ± 7.1 days, N = 41) as compared to mice on the B6 background (444.4 ± 4.6 days, N = 49) [18]. There was no significant difference in lifespan
(p>0.05) between male and female mice in either background [18]. The mean
lifespan ± standard error in the 167 mice in the B6xSJL F2 cross in this study was 492.8 ± 9.4
days. The lifespan of the G59S-hDCTN1 transgenic mice in the F2 cross was significantly
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different (p<0.05) from transgenic mice in either the B6 or the SJL background. The F2
B6xSJL mice were classified into two groups based on the reason for euthanasia. The first
group of 125 mice were euthanized due to limb paralysis or failure to right themselves when
placed on their side. This group was named “survival” and demonstrated a mean age at sacrifice of 499.9 ± 10.6 days. The second group of 42 mice were euthanized due to causes other
than limb paralysis or failure to right themselves such as; enlarged abdomens, liver tumors,
prolapsed rectum loss of greater than 30% of their peak body weight and eye ulcers. This
group was named “health_sac” and demonstrated a mean age at sacrifice of 471.5 ± 19.8 days.
There was no statistically significant difference in the age at sacrifice (p>0.05) between groups.

Distribution of the survival and health_sac phenotypes of the F2 mice
The survival phenotype distribution of the F2 mice in this study was very different from the
survival phenotype of the G93A-hSOD1 F2 mice in our previous linkage study [14]. The survival distribution of the G93A-hSOD1 F2 was intermediate between the B6 and SJL distributions (Fig 1A). In contrast, 40% of the F2 mice in this study demonstrated greater survival than
the longest-lived mouse in the B6 group (Fig 1B). This distribution also applied to the health_sac phenotype, where 38% of the mice lived longer than the longest-lived mouse in the B6
group, suggesting that combinations of B6 and SJL alleles result in phenotypes milder than the
phenotype observed in B6 mice.

Effect of sex and F2 paternal grandmother on lifespan
There was a small but not significant (p = 0.1621) difference in the life span of the F2 mice by
sex, however, male mice that required euthanasia due to limb paralysis or inability to right
themselves (survival) lived significantly longer (p = 0.0315) than females. There was no difference in the time of sacrifice of the health_sac group by sex (Table 1).
All groups demonstrate a significant difference in life span depending on the direction of
the F2 cross. Mice with the paternal grandmother (pgm) of the F2 cross in the B6 strain lived
significantly longer (p<0.05) than mice with pgm in the SJL strain (Table 2).

QTL analysis identifies regions that modify the survival and health_sac
phenotypes
Linkage analysis revealed suggestive QTLs on Chrs 17 and 18 for the survival phenotype (Fig
2, S2 Table). In addition, two dimensional scans reveal suggestive interactions between the
Chr 17 QTL and a region on Chr 4 as well as interactions between the X Chr and regions on
Chrs 5, 9, 13 and 18 (S4 Table).
All putative QTLs identified by the one-dimensional scans as well as interactions between
QTLs identified by the two-dimensional scans were fitted into a multiple regression model
using the function fitqtl. The QTL locations were then refined using the function refineqtl. As
stated in the methods, the multiple regression model require significance at the 1% level
(p<0.01) for main QTL effects and a more stringent 0.1% (p<0.001) for interaction effects.
For the survival phenotype, both the Chr 17 and 18 QTLs were significant at the 1% level
(p<0.01). Following running refineqtl the maximum likelihood position for the Chr 17 QTL
remained at 43.8 cM whereas the Chr 18 QTL was calculated to be at 25.9 cM. The effects of
the QTLs differed; the BB genotype at the Chr17 QTL demonstrated longer survival than the
SS (Fig 3), whereas at the Chr18 QTL the BB genotype demonstrated shorter survival than the
SS (Fig 4). None of the QTL� QTL interactions identified in the two-dimensional scans were
significant at the 0.1% level. The refined QTL locations and QTL intervals for the Chrs 17 and
18 QTLs of the survival phenotype are shown in Table 3.
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Fig 1. Survival curves for SOD1 and dynactin-1 transgenic mice. Survival curves for transgenic C57BL6/J, SJL/J
mice and their F2 cross with [A] the G93A human SOD1 transgene or [B] the G59S human dynactin-1 transgene.
https://doi.org/10.1371/journal.pone.0274615.g001
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Table 1. Effect of sex on life span of F2 G59S-hDCTN1 mice.
Phenotype

Female

t-Test

N

Mean±se

Males
N

Mean±se

p value

Life span

75

507.3±15.5

92

480.9±11.3

0.1621

Survival

49

528.1±17.7

76

481.7±12.8

0.0315

Health_sac

26

468.0±28.8

16

477.1±23.7

0.8266

https://doi.org/10.1371/journal.pone.0274615.t001

Linkage analysis also revealed suggestive QTLs on Chrs 4, 6, 10, 13 and 15 for the health_sac
phenotype (S3 Table) and two-dimensional scans also revealed interactions for the health_sac
phenotype between regions on Chrs 4 and 13, Chrs 5 and 10, Chr 6 and 19 as well as Chrs 13
and 19 (S4 Table).
For the health_sac phenotype, when fitted into multiple regression models, the QTLs on
Chrs 6 and 15 were significant at the 1% level (p<0.01). Following running refineqtl the maximum likelihood position for the Chr 15 health_sac QTL remained at 16.3 cM whereas the Chr
6 QTL was calculated to be at 33.5 cM. The effects of the Chr 6 and 15 QTLs differed. Mice
with the BB genotype at Chr 6 demonstrated longer life span due to health sacrifice than mice
with the SS genotype, whereas at the Chr 15 QTL mice with the BS genotype demonstrated
longer life span due to health sacrifice than mice with either the BB or SS genotype, (S1 and S2
Figs). None of the QTL� QTL interactions identified in the two-dimensional scans were significant at the 0.1% level. The refined QTL locations and QTL intervals for the Chrs 6 and 15
QTLs of the health_sac phenotype is shown in (Table 4).

Discussion
We have reported a more severe phenotype with significant acceleration of disease onset and
decreased life span in G59S-hDCTN1 mice bred onto the SJL background and a milder phenotype with delayed onset and increased life span when bred onto the B6 background [18]. The
present study genetically mapped changes in life span through genome-wide analysis of an
intercross between G59S-hDCTN1 transgenic mice on the mild phenotype (C57BL/6J) and
the severe phenotype (SJL/J) mouse strains. The result of this study demonstrates that the
causes of decreased life span in the G59S-hDCTN1 transgenic mice are complex. In contrast to
the high copy G93A-hSOD1 transgenic mice, where euthanasia is precipitated by hind limb
paralysis or inability to right itself, deteriorating health requiring euthanasia in the G59ShDCTN1 transgenic mice resulted from multiple conditions. We split lifespan into two phenotypes: euthanasia due to limb paralysis or inability to right themselves as “survival”, whereas
euthanasia due deteriorating health such that the veterinary staff recommended euthanasia as
“health_sac”.
The effect of sex on lifespan differed depending on the phenotype. Male mice in the survival
phenotype lived significantly longer (p = 0.0315) than females. This was not the case for the
health_sac phenotype. However, both phenotypes demonstrated a significant difference in life
Table 2. Effect of the paternal grandmother of the F2 cross on life span of G59S-hDCTN1 mice.
Phenotype

C57BL6/J pgm

SJL/J pgm

t-Test

N

Mean±se

N

Mean±se

Life span

99

525.2±12.6

68

445.6±11.8

p value
0.00002

Survival

67

536.2±16.1

58

458.0±10.9

0.00016

Health_sac

32

502.1±19.2

10

373.7±44.9

0.00432

https://doi.org/10.1371/journal.pone.0274615.t002
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Fig 2. Whole genome LOD plot for the survival phenotype of the G59S-hDCTN1 mice. LOD plot of a whole
genome scan for the Survival phenotype with pgm as an additive covariate and sex as an interactive covariate.
Chromosome locations are on the X axis, LOD score on the Y axis. The green line indicates suggestive QTL threshold
at a LOD of 3.2.
https://doi.org/10.1371/journal.pone.0274615.g002

span depending on the strain of the paternal grandmother (pgm). Mice with pgm in the SJL
strain had reduced life span (p<0.01) compared with mice with pgm in the B6 strain. Suggesting that genetic elements in the X chromosome that differ between strains modify phenotype,
either directly, or in combination with autosomal genes.

Fig 3. Effect plot of genotype on survival at the chromosome 17 QTL of G59S-hDCTN1 mice. Effect of the
genotype at chromosome 17, 43.8 cM on survival. The survival in days is plotted as the mean ± SE. The genotypes are
BB for homozygous B6, SS for homozygous SJL and BS for heterozygous B6/SJL.
https://doi.org/10.1371/journal.pone.0274615.g003
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Fig 4. Effect plot of genotype on survival at the chromosome 18 QTL of G59S-hDCTN1 mice. Effect of genotype at
chromosome 18, 25.9 cM on survival. The survival in days is plotted as the mean ± SE. The genotypes are BB for
homozygous B6, SS for homozygous SJL and BS for heterozygous B6/SJL.
https://doi.org/10.1371/journal.pone.0274615.g004

This study identified QTL loci on mouse Chrs 17 and 18 for the survival phenotype and on
Chrs 6 and 15 for the health sacrifice phenotype that when fitted into multiple regression models were significant at the 1% level (p<0.01). The two phenotypes clearly differed. The survival
phenotype demonstrated a significant (p<0.05) difference with sex whereas the health_sac
phenotype did not. In addition, the genetic loci identified for each phenotype were located on
different Chrs suggesting that different genetic elements modify the survival and health sacrifice phenotypes in the G59S-hDCTN1 mouse. Given that the principal aim of our study is to
identify genetic modifiers of disease expression in models of motor neuron disease, we focused
the discussion on the survival phenotype.
Our previous linkage study on G93A-hSOD1 transgenic mice identified QTLs on Chrs 17
and 7 for the survival phenotype. At both QTL locations, mice with BB alleles demonstrated
longer survival than mice with SS alleles. The allele order for the survival phenotype at the
QTL locations was BB>BS>SS. In this study, the QTL on chromosome 17 followed a slightly
different pattern, with an allele order for survival of BB = BS>SS (Fig 3). In addition, the QTL
on Chr 18, demonstrates a completely different pattern with an allele order for survival of
BS>SS>BB (Fig 4). In other words, mice that are heterozygous or homozygous for SJL alleles
at the Chr 18 QTL location demonstrated longer survival than mice with B6 alleles. On average, autosomal chromosome locations in the F2 mice are 25% BB, 50% BS and 25% SS. The
survival of mice with a BS genotype at the Chr 17 QTL is no different than mice with a BB
genotype, whereas BS mice at the Chr 18 QTL have longer survival than both SS and BB. The
fact that half of the F2 mice have BS genotype at the QTL locations may explain why many B6/
SJL F2 mice demonstrate longer survival than mice on a pure B6 background (Fig 1B).
Table 3. Multiple regression model for the survival phenotype in G59S-hDCTN1 mice.
Source
Chr 17

Additive covar

Chr 17
Chr 18

Interactive covar

Sex
Sex
Pgm

Location (cM)

Percent variance

F value

43.8

27.8–57.8

Interval (cM)

8.651

3.596

0.00840

43.8

27.8–57.8

6.303

5.241

0.00662

25.9

13.9–37.9

6.235

5.184

0.00697

Pgm

10.397

Sex

8.435

17.29
4.636

p value

6.18x10-5
0.00404

https://doi.org/10.1371/journal.pone.0274615.t003
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Table 4. Multiple regression model for the health sac phenotype in G59S-hDCTN1 mice.
Source

Additive covar

Percent variance

F value

33.5

1.5–61.5

14.89

6.861

0.00341

16.3

10.3–50.0

18.38

4.234

0.00753

16.3

10.3–50.0

14.78

6.808

0.00354

Pgm

30.76

9.446

1.38x10-4

Sex

18.64

5.724

0.00308

Chr 6
Chr 15
Chr 15

Interactive covar
Sex

Pgm
Pgm

Location (cM)

Interval (cM)

p value

https://doi.org/10.1371/journal.pone.0274615.t004

The location of the Chr 17 survival QTL on the G93A-hSOD1 mouse partly overlaps with
the Chr 17 survival QTL in the G59S-hDCTN1 mouse (Fig 5). The survival QTL in SOD1
transgenic mice demonstrates the highest LOD scores between 3 and 17 cM (Fig 5A). In contrast, the survival QTL in dynactin-1 transgenic mice demonstrate the highest LOD scores
between 28 and 58 cM (Fig 5B). However, there is an area between 17 and 40 cM were the
QTL maps overlap (Fig 5), suggesting that genetic elements in this region may modify survival
in both models of motor neuron disease.

Fig 5. LOD plots of chromosome 17 QTLs of SOD1 and dynactin-1 transgenic mice. Chromosome 17 LOD plots.
[A] Chromosome 17 Survival QTL in F2 B6xSJL G93A-hSOD1 mice. [B] Chromosome 17 Survival QTL in F2 B6xSJL
G59S-hDCTN1 mice.
https://doi.org/10.1371/journal.pone.0274615.g005
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The QTL region on Chr 17 contains 251 genes where SJL mice demonstrate non-synonymous variations (S5 Table). Ninety-six of those genes have PROVEAN or SIFT scores that predict the variations to be deleterious and/or damaging to protein function (Table 5).
The distal segment of the QTL that does not overlap with the survival QTL in SOD1 transgenic mice contains 29 genes with non-synonymous variations, nine of them demonstrated
variations predicted to be deleterious and/or damaging with LRPPRC as the most likely candidate genetic modifier of ALS. The leucine-rich pentatricopeptide repeat containing (LRPPRC)
protein regulates mitochondrial mRNA stability and an amino-acid substitution of this protein
causes the French-Canadian type of Leigh syndrome (LSFC), a progressive neurodegenerative
disorder characterized by mitochondrial complex IV deficiency [27, 28].
The proximal segment that overlaps with the survival QTL in SOD1 transgenic mice contains 222 genes with non-synonymous variations, eighty-seven of them demonstrated variations predicted to be deleterious and/or damaging (Table 5). Two genes in this segment,
NOTCH3 and Safb/SAFB1, have been associated with motor neuron disease. Mutations in
NOTCH3 have been shown to cause cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most common form of hereditary
stroke [29]. NOTCH3 mutations have also been associated with a number of neurodegenerative diseases such as; Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, ALS and
fronto-temporal lobar degeneration [29–31]. SAFB1 is an RNA binding protein implicated in
the regulation of transcription, stress response, DNA repair and RNA processing [32]. A recent
study suggests that SAFB1 tethers FUS to the chromatin compartment thorough N-terminal
DNA-binding motif, indicating that SAFB1 could be a FUS’s functional platform in the chromatin compartment regulating RNA splicing and ligand-dependent transcription. This interaction may shed light on the etiological significance of nuclear matrix-associated proteins in
ALS pathogenesis [33].
This region also contains the mouse major histocompatibility complex (H2) [34, 35].
Twenty-two genes within H2 demonstrated non-synonymous variations deemed to be deleterious and/or damaging, with some regions such as H2-K1, H2-d1, H2-Q2 and H2-Q4 having
20 or more variations each (Table 5). The Major Histocompatibility Complex has been shown
to have a protective role in ALS [36, 37].
In addition, there are several genes in this segment whose function, when altered, can affect
motor neuron survival such as; Marchf2, Ndufa7, Vps52, Tap1, Nelfe, Ehmt2, Vars2, Mdc1,
Adgrf1, Aars2, Hsp90ab1, Abcc10, Cul9/Parc, Usp49, Foxp4, Trem3, Treml1 and Ticam1/
TRIF.
MARCHF2 (MARCH-II) is a likely regulator of trafficking between the trans-Golgi network and endosomes [38] and may also function as a molecular bridge with ubiquitin ligase
activity [39]. NDUFA7 is a subunit of mitochondrial complex I [40]. Genetic variants of Complex I genes may influence the nature of tissue response to inflammation in the central nervous
system [41]. Vps52 is a subunit of the GARP and EARP complexes that has been shown to be
involved in the regulation of neurite outgrowth [42]. The transporter associated with antigen
processing 1 (TAP1) gene is involved in the pumping of degraded cytosolic peptides across the
endoplasmic reticulum into the membrane-bound compartment where class I molecules
assemble. The TAP1 and TAP2 proteins form the heterodimer transporter associated with
antigen processing (TAP) complex Loss of TAP function leads to a loss of cell surface expression of MHC class I molecules [43]. NELFE is an essential component of the negative elongation factor (NELF) complex, which allows cells to coordinate and appropriately respond to
signals by modulating the rate of transcriptional pause release [44]. Euchromatic histonelysine N-methyltransferase 2 (EHMT2) along with EHMT1 comprises a histone
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Table 5. Protein coding genes in the Chr17 QTL of G59S-hDCTN1 mice demonstrating non-synonymous variations deemed to be deleterious and/or damaging.
Mouse Gene
Symbol

Mouse Gene ID

Human Gene
Symbol

Mouse Gene Name

Chr 17 Location
GRCm39

Del/Dam #
Vars

Rrp1b

72462

RRP1B

ribosomal RNA processing 1B

32255074–32281839

2

Notch3

18131

NOTCH3

notch 3

32339794–32385826

1

Zfp799

240064

ZNF799

zinc finger protein 799

33034423–33049235

1

Cyp4f13

170716

CYP4F3

cytochrome P450, family 4, subfamily f, polypeptide 13

33143662–33166376

1

Phf8-ps

74042

PHD finger protein 8, pseudogene

33283117–33286999

2

Morc2b

240069

microrchidia 2B

33332325–33358657

1

Zfp955a

77652

zinc finger protein 955A

33458692–33474119

1

Zfp955b

100043468

zinc finger protein 955B

33508518–33526215

2

Marchf2

224703

MARCHF2

membrane associated ring-CH-type finger 2

33904666–33937644

2

Ndufa7

66416

NDUFA7

NADH: ubiquinone oxidoreductase subunit A7

34043546–34057291

1

Vps52

224705

VPS52

VPS52 GARP complex subunit

34174786–34186009

10

H2-K1

14972

HLA-A

histocompatibility 2, K1, K region

34214991–34219321

24

Rxrb

20182

RXRB

retinoid X receptor beta

34250786–34257373

1

Tap1

21354

TAP1

transporter 1, ATP-binding cassette, sub-family B (MDR/
TAP)

34406527–34416199

3
1

MORC2

Gm15821

100502931

predicted gene 15821

34430286–34433433

H2-Ob

15002

HLA-DOB

histocompatibility 2, O region beta locus

34457877–34473388

3

H2-Ab1

14961

HLA-DQB1

histocompatibility 2, class II antigen A, beta 1

34476663–34488393

4

H2-Aa

14960

HLA-DQA1

histocompatibility 2, class II antigen A, alpha

34501718–34506797

3

H2-Eb1

14969

HLA-DRB5

histocompatibility 2, class II antigen E beta

34524841–34535648

3

H2-Eb2

381091

histocompatibility 2, class II antigen E beta2

34544639–34560386

1

BC051142

407788

cDNA sequence BC051142

34617794–34679708

4

Btnl4

632126

butyrophilin-like 4

34685536–34696292

11

Btnl6

624681

butyrophilin-like 6

34726778–34736326

9

Notch4

18132

NOTCH4

notch 4

34783242–34807477

1

Tnxb

81877

TNXB

tenascin XB

34879431–34938789

4

Nelfe

27632

NELFE

negative elongation factor complex member E, Rdbp

35069367–35075348

3

Ehmt2

110147

EHMT2

euchromatic histone lysine N-methyltransferase 2

35117445–35133028

1

D17H6S56E-5

110956

D6S56E 5

DNA segment, Chr 17, human D6S56E 5

35215654–35219722

1

Ly6g6f

433099

LY6G6F

lymphocyte antigen 6 complex, locus G6F

35299456–35304586

1

H2-D1

14964

HLA-A

histocompatibility 2, D region locus 1

35481706–35486475

20

H2-Q1

15006

HLA-A

histocompatibility 2, Q region locus 1

35539381–35544075

2

H2-Q2

15013

HLA-A

histocompatibility 2, Q region locus 2

35561218–35565738

25

H2-Q4

15015

HLA-A

histocompatibility 2, Q region locus 4

35598593–35604266

33

H2-Q6

110557

HLA-A

histocompatibility 2, Q region locus 6

35643826–35649031

2

Muc21

672682

MUC21

mucin 21

35928815–35937529

11

Mucl3

268949

MUCL3

mucin like 3

35946644–35954587

2

Vars2

68915

VARS2

valyl-tRNA synthetase 2, mitochondrial

35966526–35978484

2

Gtf2h4

14885

GTF2H4

general transcription factor II H, polypeptide 4

35978622–35984631

1

Mdc1

240087

MDC1

mediator of DNA damage checkpoint 1

36152407–36170562

1

Ppp1r18

76448

PPP1R18

protein phosphatase 1, regulatory subunit 18

36176485–36186488

1

H2-T24

15042

histocompatibility 2, T region locus 24

36316587–36331452

1
11

H2-T23

15040

H2-T22

15039

Gm11127

100529082

Gm7030

630294

2410017I17Rik

675325

HLA-E

histocompatibility 2, T region locus 23

36340665–36343747

histocompatibility 2, T region locus 22

36348020–36353639

17

HLA-F

predicted gene 11127 (H2-K1)

36366708–36369263

3

HLA-F

predicted gene 7030 (H2-t9)

36420611–36440317

1

RIKEN cDNA 2410017I17 gene

36455910–36474068

35
(Continued )
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Table 5. (Continued)
Mouse Gene
Symbol

Mouse Gene ID

Gm8909

667977

H2-T3

15043

Human Gene
Symbol
HLA-A

Mouse Gene Name

Chr 17 Location
GRCm39

Del/Dam #
Vars

predicted gene 8909 (H2-gs17)

36475335–36479429

21

histocompatibility 2, T region locus 3

36496464–36501179

13

H2-M10.1

14985

histocompatibility 2, M region locus 10.1

36633750–36637047

1

H2-M11

224754

histocompatibility 2, M region locus 11

36857967–36860142

1

H2-M1

224756

histocompatibility 2, M region locus 1

36980900–36983111

1

H2-M10.5

224761

histocompatibility 2, M region locus 10.5

37083802–37087126

1

Polr1has

76416

RNA polymerase I subunit H, antisense

37269484–37276517

3

Olfr90

258469

olfactory receptor 90

37394763–37399391

1

Olfr92

258448

olfactory receptor 92

37421404–37430975

2

Olfr93

258051

olfactory receptor 93

37451309–37472385

1

Adgrf1

77596

ADGRF1

adhesion G protein-coupled receptor F1

43581220–43635628

1

Supt3

109115

SUPT3H

SPT3, SAGA and STAGA complex component

45088039–45430177

3

Aars2

224805

AARS2

alanyl-tRNA synthetase 2, mitochondrial

45817767–45831769

2

Hsp90ab1

15516

HSP90AB1

heat shock protein 90 alpha (cytosolic), class B member 1

45878701–45884197

12

RIKEN cDNA 1600014C23 gene

46043790–46044770

2

ATP-binding cassette, sub-family C (CFTR/MRP),
member 10

46614147–46639278

1

OR2H2

1600014C23Rik

72240

Abcc10

224814

Gm5093

328825

predicted gene 5093

46750504–46751023

1

Cul9

78309

CUL9/PARC

cullin 9

46811498–46857314

5

Pex6

224824

PEX6

peroxisomal biogenesis factor 6

47022389–47036467

2

Cnpy3

72029

CNPY3

canopy FGF signaling regulator 3

47046631–47063140

1

Rpl7l1

66229

RPL7L1

ribosomal protein L7-like 1

47084833–47093598

1

Gm16494

105246356

non-histone chromosomal protein HMG-17 pseudogene

47327623–47327881

2

Gm4945

240110

ribosomal protein L29 pseudogene

47353513–47353965

3

AI661453

224833

expressed sequence AI661453

47747540–47781563

3

Ccnd3

12445

CCND3

cyclin D3

47815976–47910616

1

Usp49

224836

USP49

ubiquitin specific peptidase 49

47941615–47997663

1

Prickle4

381104

PRICKLE4

prickle planar cell polarity protein 4

47999442–48005661

2

Frs3

107971

FRS3

fibroblast growth factor receptor substrate 3

47999955–48015211

1

Foxp4

74123

FOXP4

forkhead box P4

48178058–48235570

1

9830107B12Rik

328829

RIKEN cDNA 9830107B12 gene

48436215–48453439

7

A530064D06Rik

328830

RIKEN cDNA A530064D06 gene

48456296–48474443

3

Trem3

58218

triggering receptor expressed on myeloid cells 3

48554805–48565869

1

ABCC10

Treml1

71326

TREML1

triggering receptor expressed on myeloid cells-like 1

48666944–48674204

1

Pp2d1

110332

PP2D1

protein phosphatase 2C-like domain containing 1

53814488–53846479

1

Sult1c2

69083

SULT1C2

sulfotransferase family, cytosolic, 1C, member 2

54136665–54153367

1

Vmn2r118

383258

vomeronasal 2, receptor 118

55897370–55932192

4

Fsd1

240121

FSD1

fibronectin type 3 and SPRY domain-containing protein

56293509–56303881

1

Ticam1

106759

TICAM1

toll-like receptor adaptor molecule 1

56576319–56583786

2

Safb

224903

SAFB

scaffold attachment factor B

56891825–56913294

1

Catsperd

106757

CATSPERD

cation channel sperm associated auxiliary subunit delta

56935143–56971456

1

Arhgap28

268970

ARHGAP28

Rho GTPase activating protein 28

68149708–68311115

3

Gm16519

546695

ribosomal protein L12 pseudogene

71236053–71236541

2

Alk

11682

ALK

anaplastic lymphoma kinase

72175967–72911622

1

Vit

74199

VIT

Vitrin

78815493–78934837

1

Ndufaf7

73694

NDUFAF7

NADH: ubiquinone oxidoreductase complex assembly
factor 7

79244565–79255481

1
(Continued )
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Table 5. (Continued)
Mouse Gene
Symbol

Mouse Gene ID

Human Gene
Symbol

Mouse Gene Name

Chr 17 Location
GRCm39

Del/Dam #
Vars

Thada

240174

THADA

thyroid adenoma associated

84497504–84773633

1

Lrpprc

72416

LRPPRC

leucine-rich PPR-motif containing

85012675–85098217

1

Tmem247

78469

TMEM247

transmembrane protein 247

87224776–87229802

1

Mcfd2

193813

MCFD2

multiple coagulation factor deficiency 2

87561871–87573363

1

Gm10184

100043906

karyopherin (importin) alpha 2 pseudogenes

90215890–90217877

1

https://doi.org/10.1371/journal.pone.0274615.t005

methyltransferase complex (GLP/G9a) that methylates lysine residues of histone H3. This
methylation is associated with gene silencing in euchromatin [45].
EHMT2 has been shown to be an epigenetic regulator of VEGFA alternative splicing [46].
VEGF has been shown to be a modifier of motoneuron degeneration both in human ALS and
the G93A-hSOD1 mouse model of ALS [47]. The VARS2 nuclear gene encodes mitochondrial
valyl-tRNA (Val-tRNA) synthetase. Mutations in this gene cause combined oxidative phosphorylation deficiency-20 [48] and are also associated with early-onset mitochondrial encephalopathies [49]. The MDC1 protein is part of the DNA damage response (DDR) pathway.
MDC1 plays an early and important role in the DDR [50, 51]. ADGRF1 (GPR110) has been
shown to regulate immune function in both brain and periphery [52]. The mitochondrial alanyl-transfer (t)RNA synthetase 2 (AARS2) has been linked to leukoencephalopathy [53]. The
heat shock protein (Hsp) HSP90 is involved in protein folding, refolding, transport as well as
protein degradation [54]. ABCC10 is a member of the superfamily of ATP-binding cassette
(ABC) transporters, expressed in the blood brain barrier, whose function is to transport molecules across extra- and intra-cellular membranes [55]. PARC regulates p53 subcellular localization and apoptosis [56] and mediates the degradation of cytochrome c promoting neuronal
survival [57]. USP49 is a histone H2B-specific deubiquitinase and has a critical role for H2B
deubiquitination in cotranscriptional pre-mRNA processing events [58]. FOXP transcription
factors are a protein subfamily known to coordinate the development of several organs including the Central Nervous System [59, 60]. These transcription factors, including FOXP4, are
associated with neurodevelopmental disorders [61].
Variants within the TREM gene cluster are associated with the risk of developing Alzheimer’s disease, making them a therapeutic target for the treatment of neurodegenerative diseases [62, 63]. TICAM1/TRIF encodes an adaptor protein containing a Toll/interleukin-1
receptor (TIR) homology domain. TIR-domain-containing adapter-inducing interferon-β
(TRIF) is an adapter in responding to activation of toll-like receptors. Mutations in this gene
are associated with acute infection-induced encephalopathies. TRIF is dynamically modified
by ubiquitination and deubiquitination, which plays a critical role in regulating its activity.
Toll/IL-1R domain-containing adaptor-inducing IFN-β (TRIF)-dependent signaling is
required for TLR-mediated production of type-I IFN and several other proinflammatory
mediators. The TRIF pathway contributes to control of both viral and bacterial pathogens
through promotion of inflammatory mediators and activation of antimicrobial responses [64].
The QTL on Chr 18 contains 85 genes were SJL mice demonstrate non-synonymous variations (S6 Table). Thirty of those genes have PROVEAN or SIFT scores that predict the variations to be deleterious and/or damaging to protein function (Table 6).
MATR3 and the protocadherin family of genes are the most likely ALS genetic modifying
candidates in this QTL. MATR3 is the one gene in the Chr 18 QTL that has been directly
linked to ALS [65, 66]. Mutations in the RNA/DNA-binding protein MATR3, which is known
to interacts with TDP-43, has been shown to cause ALS [67].
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Table 6. Protein coding genes in the Chr18 QTL of G59S-hDCTN1 mice demonstrating non-synonymous variations deemed to be deleterious and/or damaging.
Mouse Gene
Symbol

Mouse Gene ID

Human Gene
Symbol

Mouse Gene Name

Chr 18 Location
GRCm39

Del/Dam #
Vars

Gm10036

100040551

ribosomal protein L11 pseudogene

15965851–15966384

Gm10549

433171

predicted gene 10549

33597216–33607763

1

Brd8

78656

bromodomain containing 8

34731668–34757654

1
1

BRD8

1

Kdm3b

277250

KDM3B

KDM3B lysine (K)-specific demethylase 3B

34910100–34971713

Egr1

13653

EGR1

early growth response 1

34992876–34998037

1

Hspa9

15526

HSPA9

heat shock protein 9

35070467–35087410

1

Matr3

17184

MATR3

matrin 3

35695191–35726888

5

Wdr55

67936

WDR55

WD repeat domain 55

36893273–36896863

1

Pcdha1

116731

PCDHA1

protocadherin alpha 1

37063237–37320714

2

Pcdhb2

93873

PCDHB2

protocadherin beta 2

37427865–37430677

3

Pcdhb3

93874

PCDHB3

protocadherin beta 3

37433852–37437638

4

Pcdhb4

93875

PCDHB4

protocadherin beta 4

37440508–37444225

5

Pcdhb5

93876

PCDHB5

protocadherin beta 5

37453434–37456968

7

Pcdhb6

93877

PCDHB6

protocadherin beta 6

37466974–37470727

3

Pcdhb8

93879

PCDHB8

protocadherin beta 8

37488174–37491657

9

Pcdhb9

93880

PCDHB9

protocadherin beta 9

37533908–37536962

12
1

Diaph1

13367

DIAPH1

diaphanous related formin 1

37976654–38068529

Pcdh12

53601

PCDH12

protocadherin 12

37568674–37571707

1

Spink14

433178

SPINK14

serine peptidase inhibitor, Kazal type 14

44160936–44165484

1
3

Dtwd2

68857

DTWD2

DTW domain containing 2

49829212–49888668

Srfbp1

67222

SRFBP1

serum response factor binding protein 1

52598765–52625003

1

Fbn2

14119

FBN2

fibrillin 2

58141695–58343559

1

Cdx1

12590

CDX1

caudal type homeobox 1

61151934–61169271

1

Arhgef37

328967

ARHGEF37

Rho guanine nucleotide exchange factor (GEF) 37

61624728–61669665

1

Gm9949

225609

predicted gene 9949

62313197–62317476

3

Alpk2

225638

ALPK2

alpha-kinase 2

65398600–65527137

2

Oacyl

319888

O-acyltransferase like

65831339–65884672

1

Ldlrad4

52662

LDLRAD4

low density lipoprotein receptor class A domain
containing 4

68066328–68401701

1

Rnmt

67897

RNMT

RNA (guanine-7-) methyltransferase

68433426–68457923

2

Poli

26447

POLI

polymerase (DNA directed), iota

70641751–70663691

1

https://doi.org/10.1371/journal.pone.0274615.t006

There are 14 genes in the protocadherin family demonstrating non-synonymous variations
in SJL/J mice within the Chr 18 QTL. Protocadherins are the largest mammalian subgroup of
the cadherin superfamily [68]. Preventing the interaction of axons and dendrites from the
same neuron during development, is mediated through the stochastic single-neuron expression of clustered protocadherin protein isoforms [69]. Most of the protocadherin proteins
demonstrating variations belong to the alpha and beta clusters. The one gene in the gamma
cluster (Pcdhgc3) demonstrated one non-synonymous SNP resulting in a single amino acid
change (S651N) that was predicted by PROVEAN to be neutral, tolerated. Nine genes in the
protocadherin family; Pcdha1, Pcdhb2, Pcdhb3, Pcdhb4, Pcdhb5, Pcdhb6, Pcdhb8, Pcdhb9
and Pcdh12 demonstrated non-synonymous variations with PROVEAN or SIFT scores that
predict the variations to be deleterious and/or damaging to protein function. Protocadherins
within the alpha cluster have been shown to contribute to neural circuit development [70].
Protocadherins in the beta cluster contribute to specifying the identity and diversity of
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individual neurons [71] and members of this cluster have been reported to control axon
growth in zebrafish motor neurons [72].
In addition, there are several genes in this QTL demonstrating variations predicted to be
deleterious and/or damaging, whose function, when altered, can affect motor neuron survival
such as; Brd8, Kdm3b, Egr1, Hsp9 and Diaph1. BRD8 (p120) has been linked with DNA repair
[73–75]. KDM3B has been identified as an antioxidant gene [76]. EGR1 is a transcription factor also known as nerve growth factor-induced protein A (NGFIA). EGR1 transcriptional regulation is complex and involves; transcription factor binding, cofactors recruitment,
chromatin dynamics including histone methylation, acetylation and phosphorylation, as well
as nucleosome positioning [77]. HSPA9 (Mortalin) is a mitochondrial chaperone of the heat
shock protein 70 family [78, 79]. Mutations in HSPA9 may contribute to the risk of developing
Parkinson’s disease [80]. Mutations in DIAPH1 results in mitochondrial dysfunction and
immunodeficiency which can lead to seizures, cortical blindness, hearing loss and microcephaly syndrome [81, 82].
Our results shows that mice with SJL genotype at the Chr17 QTL demonstrated shorter survival than mice with C57BL6 genotype, whereas at the Chr18 QTL mice with the SJL genotype
demonstrated longer survival than mice with the C57BL6 genotype. The phenotypic changes
can result from alterations in protein coding genes within the QTLs, however they could also
arise from altered non-coding RNAs such as microRNAs or long non-coding RNAs.
In addition, altered survival does not necessarily mean that all SJL-derived protein coding
genes and/or non-coding RNAs at the Chr 17 QTL are deleterious or all beneficial at the Chr
18 QTL. It means that the total contribution of genetic elements that differ in SJL mice at the
Chr 17 QTL results in reduced survival, whereas the total contribution of those at the Chr 18
QTL promotes increased survival. We hypothesize that the variations in survival demonstrated
by mice with SJL alleles within the Chr 17 and 18 QTLs are due to either allelic non-synonymous genetic polymorphism(s) of protein coding genes and/or non-coding RNAs or their differential expression.
We further hypothesize that some of the genetic modifiers located in the Chr 17 region
where the SOD1 and dynactin-1 QTLs overlap, will be shared by these two MND models
despite the fact that motor neuron degeneration is caused by mutations in different proteins.
We are currently undertaking studies using interval specific congenic (ISC) mice on a
C57BL6/J background with Chr 17 SJL intervals in the region where the SOD1 and dynactin-1
QTLs overlap. We have bred the SOD1 and dynactin-1 transgenes into these ISC lines in order
to determine which regions modify the survival of these mice. Our goal is to generate ISC mice
with 1–3 Mb intervals that preserve the altered phenotype. These mice can then be used for the
identification of genetic modifiers of motor neuron disease. The identification of genetic modifiers of motor neuron disease, especially those modifiers that are shared by SOD1 and dynactin-1 transgenic mice, may help to develop biomarkers predictive of disease progression. In
addition, they will identify pathways that are important in motor neuron degeneration and
lead to novel targets for therapies that can alter the course of this devastating illness.
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